ICU Norepinephrine Load (ICU_NE_LOAD)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Circulatory Collapse and Shock

Treatments: Drug: Circulatory shock with norepinephrine in ICU

Study type: Observational

Funder types: Other

Identifiers

NCT05032261

LOCAL/2021/DC-01

Details and patient eligibility

About

Norepinephrine is recommended as first-line vasopressor in critically ill patients, regardless of shock etiology. Its advantages over dopamine and/or epinephrine have been demonstrated, especially by reducing tachycardia events. The current guidelines recommend a mean arterial pressure of at least 65 mmHg that in the resuscitation from sepsis-induced hypoperfusion. Some study reported that delay in initiation of vasopressor therapy was associated with an increase mortality risk in patient with septic shock .The recent experts' opinion suggest that " vasopressors should be started early, before (complete) completion of fluid ressuscitation ".

In the event of refractory septic shock, high-dose vasopressors may be used. The precise maximal dose of norepinephrine associated with mortality excess has been poorly studied. High doses have been defined by a cutoff value ranging from 0.5 μg/kg/min to 2 μg/kg/min and recently by 1 μg/kg/min for mortality at 90% and by 0,75 μg/kg/min for mortality at 60%. Furthermore, an increasing vasopressor dosing intensity during the first 24 hours after shock septic was associated with increased mortality depending of fluid administration. If a threshold value of norepinephrine score can be obtained, it could indicate the association with another vasopressor such as vasopressin or surrogates.

The primary aim of the present study aimed to confirm if a given norepinephrine dose is associated with mortality. The secondary aims were the link between mortality and norepinephrine duration, cumulative dose in order to build a score that predicts a futility of increasing norepinephrine dose.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Age > 18 years
• circulatory shock and admitted in ICU
• with norepinephrine

Exclusion Criteria : Patient without norepinephrine or missing data.

Trial design

100 participants in 2 patient groups

Group 1: surviving Patients

Description:

Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine

Treatment:

Drug: Circulatory shock with norepinephrine in ICU

Group 2: Deceased patients

Description:

Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine

Treatment:

Drug: Circulatory shock with norepinephrine in ICU